BMY Related Press Releases
-
Bristol-Myers Squibb Grants Help K-12 Educators Bring Science to Life and Help Students Explore Their Interests in the Sciences and Science-Based Careers
-
Litigation Settlements, Data Compliance Reviews, and Clinical Trials Pave Way for Solid Footing in Healthcare - Research Report on Pfizer, Merck, Bristol-Myers Squibb, Keryx and Pacira Pharmaceuticals
-
Bristol-Myers Squibb and AbbVie Announce Progression-Free Survival Data from Phase 2 Open-Label Study of Investigational Agent Elotuzumab in Combination with Lenalidimide and Dexamethasone in Previous
-
AstraZeneca and Bristol-Myers Squibb to Present New Data at American Diabetes Association 73rd Scientific Sessions®
-
Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia(R) SC (abatacept) in China
-
Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia® SC (abatacept) in China
-
AstraZeneca and Bristol-Myers Squibb Statement on Proposal by the American Diabetes Association for Independent Review of Incretin-Based Therapies
-
ORENCIA® (abatacept) Shows Comparable Efficacy to Humira® (adalimumab) in Year Two Data from Head-to-Head Study in Patients with Moderate to Severe Rheumatoid Arthritis
-
RBCC Explores New Funding for Expansion
-
Bristol-Myers Squibb to Take Part in Goldman Sachs Global Healthcare Conference
-
RBCC Poised To Gain Share Of $142 Billion Market
-
U.S. FDA Grants Priority Review to Bristol-Myers Squibb and AstraZeneca’s Metreleptin, an Investigational Agent for Treatment of Metabolic Disorders Associated with Rare Forms of Lipodystrophy
-
Bristol-Myers Squibb Announces Phase 1 Results from First Trial Combining Immune Checkpoint Inhibitors, Investigational Agent Nivolumab and Yervoy® (ipilimumab), in Patients with Advanced Melanoma
-
RBCC to Drive Growth Through Personalized Medicine
-
RBCC Opens Talks to Acquire Tech Innovators in $142 Billion Drug Delivery Market
-
Bristol-Myers Squibb Announces Intention to Voluntarily Delist Preferred Stock
-
Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights
-
Bristol-Myers Squibb Advances Leadership Position in Immuno-Oncology with Data to be Presented at 2013 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Bristol-Myers Squibb to Present at UBS Global Health Care Conference
-
RBCC Partner n3D Signs U.S. Distribution Agreement
-
Bristol-Myers Squibb to Present at Bank of America Merrill Lynch Health Care Conference
-
Bristol-Myers Squibb and Pfizer Announce Publication of ARISTOTLE Subanalysis in Circulation
-
Sub-Group Analysis Shows Investigational Metreleptin Treatment Demonstrated Reductions in HbA1c, Triglycerides and Liver Function Tests in Pediatric Patients with Lipodystrophy During a 12-Month Perio
-
World’s Premiere Science Journal Touts Revolutionary Innovations by RBCC Partner Nano3D
-
Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates
-
Bristol-Myers Squibb Receives US FDA sNDA Approval for Use of SUSTIVA® (efavirenz) in HIV-1 Infected Pediatric Patients
-
RBCC: Personalized Medicine Poised to Revolutionize Insurance & Pharmaceuticals
-
Bristol-Myers Squibb Reports First Quarter 2013 Financial Results
-
RBCC Looks Overseas for Potentially Lucrative Licensing Opportunities
-
Former Pro Football Coach Bill Cowher Tells Men "No Excuses" When It Comes To Getting Screened For Melanoma
-
Former Pro Football Coach Bill Cowher Tells Men “No Excuses” When It Comes to Getting Screened for Melanoma
-
High Rates of SVR Demonstrated in Phase II Study with Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Inf
-
Bristol-Myers Squibb Funds Green Schools Fellowship to Help New Jersey School Districts Create Healthier, More Sustainable Learning Environments
Back to BMY Stock Lookup
